

CHOP-like chemotherapy with or without rituximab in  
diffuse large-B-cell lymphoma: 6-year results of an open  
MabThera International Trial (MInT) Group

Lancet Oncology, The  
12, 1013-1022

DOI: [10.1016/s1470-2045\(11\)70235-2](https://doi.org/10.1016/s1470-2045(11)70235-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2013, 7, 347.	0.6	6
2	Rituximab in DLBCL: 6 years on. Lancet Oncology, The, 2011, 12, 984-985.	5.1	4
3	Successful Treatment of Cryoglobulinaemia with Rituximab. Case Reports in Nephrology and Urology, 2012, 2, 72-77.	1.5	3
4	Treatment of Diffuse Large B-cell Lymphoma. , 2012, 17, 90-97.		0
5	Chemotherapy Alone for Localized Diffuse Large B-Cell Lymphoma. Cancer Journal (Sudbury, Mass ), 2012, 18, 421-426.	1.0	21
6	Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkinâ€™s lymphoma. Clinical Investigation, 2012, 2, 49-58.	0.0	6
7	Rituximab in treatment of primary gastric diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 2175-2181.	0.6	10
8	Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Medical Weekly, 2012, 142, w13511.	0.8	27
9	Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?. Oncologist, 2012, 17, 1562-1573.	1.9	41
10	The evaluation and optimal use of rituximab in lymphoid malignancies. Blood and Lymphatic Cancer: Targets and Therapy, 2012, , 1.	1.2	2
11	Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions. Cancer Control, 2012, 19, 204-213.	0.7	99
12	Which treatment for high-risk patients with DLBCL?. Lancet Oncology, The, 2012, 13, 1180-1182.	5.1	0
13	Palliative chemotherapy is not the best choice. Journal of Geriatric Oncology, 2012, 3, S18.	0.5	0
14	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 3986-3996.	0.6	301
15	The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Annals of Hematology, 2012, 91, 1731-1739.	0.8	31
16	Diffuse large B cell lymphoma: molecular targeted therapy. International Journal of Hematology, 2012, 96, 552-561.	0.7	19
17	Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma. International Journal of Hematology, 2012, 96, 241-246.	0.7	2
18	The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Annals of Hematology, 2012, 91, 1383-1391.	0.8	39

#	ARTICLE	IF	CITATIONS
19	Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?. Hematology American Society of Hematology Education Program, 2012, 2012, 410-416.	0.9	18
20	Lymphoma of the Thyroid and Head and Neck. Clinical Oncology, 2012, 24, 345-351.	0.6	32
21	<scp>SIL</scp> index, comprising stage, soluble interleukinâ€2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large <scp>B</scp>â€cell lymphoma. Cancer Science, 2012, 103, 1518-1523.	1.7	23
22	Rituximab in combination with chemotherapy versus chemotherapy alone in HIVâ€associated nonâ€Hodgkin lymphoma: A pooled analysis of 15 prospective studies. American Journal of Hematology, 2012, 87, 330-333.	2.0	27
23	Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study. World Journal of Surgical Oncology, 2013, 11, 90.	0.8	22
24	Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy. Leukemia and Lymphoma, 2013, 54, 1684-1690.	0.6	23
26	Anti-CD20 monoclonal antibodies: Beyond B-cells. Blood Reviews, 2013, 27, 217-223.	2.8	55
27	Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Annals of Hematology, 2013, 92, 1529-1536.	0.8	68
28	Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma. Annals of Hematology, 2013, 92, 239-244.	0.8	30
29	Relapsed and refractory aggressive NHL: Time for a change. Transfusion and Apheresis Science, 2013, 49, 72-79.	0.5	15
30	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer, 2013, 119, 1195-1202.	2.0	136
31	Prognosis in diffuse large Bâ€cell lymphoma. Cancer, 2013, 119, 1129-1131.	2.0	2
32	Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia, 2013, 27, 1902-1909.	3.3	197
33	Rituximab in the treatment of non-Hodgkin's lymphoma â€“ a critical evaluation of randomized controlled trials. Expert Opinion on Biological Therapy, 2013, 13, 803-811.	1.4	49
34	Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessibility. Leukemia and Lymphoma, 2013, 54, 83-89.	0.6	10
35	Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement. Journal of Clinical Oncology, 2013, 31, 4115-4122.	0.8	95
36	Prognostic factors for patients with diffuse large <scp>B</scp> cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. British Journal of Haematology, 2013, 160, 608-617.	1.2	67
37	Diffuse large B-cell lymphoma. Critical Reviews in Oncology/Hematology, 2013, 87, 146-171.	2.0	323

#	ARTICLE	IF	CITATIONS
38	CHOP intensification: not yet state of the art. <i>Lancet Oncology</i> , The, 2013, 14, 445-447.	5.1	3
39	Successful Management of Gastric Perforation in Stage IV Diffuse Large B-Cell Lymphoma With Chemoradiation Therapy, Percutaneous Endoscopy Gastrostomy for Gastric Drainage, and Percutaneous Endoscopy Jejunostomy for Nutrition. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 327-330.	0.2	3
40	Is primary prophylaxis with granulocyte colony stimulating factor (G-CSF) indicated in the treatment of lymphoma?. <i>Transfusion and Apheresis Science</i> , 2013, 49, 51-55.	0.5	9
41	Lymphoma studies by the Australasian Leukaemia and Lymphoma Group. <i>Transfusion and Apheresis Science</i> , 2013, 49, 110-112.	0.5	0
42	Râ€œCHOP therapy alone in limited stage diffuse large Bâ€œcell lymphoma. <i>British Journal of Haematology</i> , 2013, 161, 383-388.	1.2	23
43	Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. <i>OncoTargets and Therapy</i> , 2013, 6, 289.	1.0	14
44	Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2122-2130.	0.6	16
45	Long-Term Remission After Multiple Relapses in an Elderly Patient With Lymphomatoid Granulomatosis After Rituximab and High-Dose Cytarabine Chemotherapy Without Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, e390-e393.	0.8	7
46	Singleâ€œagent lenalidomide is active in patients with relapsed or refractory aggressive nonâ€œHodgkin lymphoma who received prior stem cell transplantation. <i>British Journal of Haematology</i> , 2013, 162, 639-647.	1.2	35
49	Primary Diffuse Large B-Cell Lymphoma of the Ascending Colon. <i>Rare Tumors</i> , 2013, 5, 85-88.	0.3	22
50	Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 299.	0.1	18
51	Fifteenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Non-Hodgkin's Lymphoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1159-1170.	3.0	20
52	Cytosine Arabinoside Promotes Cytotoxic Effect of T Cells on Leukemia Cells Mediated by Bispecific Antibody. <i>Human Gene Therapy</i> , 2013, 24, 751-760.	1.4	8
53	Strikingly high false positivity of surveillance FDGâ€œPET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2013, 88, 400-405.	2.0	78
54	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e22789.	2.1	92
55	Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. <i>Haematologica</i> , 2013, 98, 765-770.	1.7	82
56	R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. <i>Blood Research</i> , 2014, 49, 107.	0.5	10
57	Clinical Features and Outcomes of 9 Patients with Immunodeficiency-Associated Lymphoproliferative Disorders Treated at a Single Institution. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2014, 54, 187-196.	0.3	5

#	ARTICLE	IF	CITATIONS
58	Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. <i>Blood Research</i> , 2014, 49, 115.	0.5	3
59	Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. <i>Oncotarget</i> , 2014, 5, 7368-7380.	0.8	7
60	Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma. <i>Acta Oncologica</i> , 2014, 53, 1093-1099.	0.8	10
61	Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2428-2437.	0.6	8
62	Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study). <i>Oncologist</i> , 2014, 19, 291-298.	1.9	70
63	Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2071-2078.	0.6	7
64	Long-term results of the R-CEOP90 in the treatment of young patients with chemotherapy-naïve diffuse large B cell lymphoma: A phase II study. <i>Leukemia and Lymphoma</i> , 2014, 55, 2387-2388.	0.6	3
65	Features and outcomes of diffuse large B-cell lymphoma of the thyroid in a large contemporary cohort. <i>Leukemia and Lymphoma</i> , 2014, 55, 283-287.	0.6	9
66	Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?. <i>Leukemia and Lymphoma</i> , 2014, 55, 471-473.	0.6	0
67	Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study. <i>Leukemia and Lymphoma</i> , 2014, 55, 1838-1843.	0.6	16
68	Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2728-2738.	0.6	44
69	Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. <i>American Journal of Hematology</i> , 2014, 89, E239-43.	2.0	81
70	Insurance status is related to diffuse large B-cell lymphoma survival. <i>Cancer</i> , 2014, 120, 1220-1227.	2.0	47
71	Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. <i>British Journal of Haematology</i> , 2014, 167, 327-336.	1.2	42
72	Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 509-514.	0.6	61
73	Adolescents and Young Adults with Non-Hodgkin's Lymphoma: Slipping between the Cracks. <i>Acta Haematologica</i> , 2014, 132, 279-291.	0.7	5
74	Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. <i>Oncolmmunology</i> , 2014, 3, e955684.	2.1	44
75	Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era. <i>Hematology</i> , 2014, 19, 412-416.	0.7	11

#	ARTICLE	IF	CITATIONS
76	Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA. <i>Lymphoma</i> , 2014, 2014, 1-12.	0.2	13
77	Limited Positron Emission Tomography-Computed Tomography for Restaging of Lymphoma: A Strategy for Reducing Radiation Exposure among Patients with Early-Stage Curable Lymphoma. <i>Acta Haematologica</i> , 2014, 131, 239-244.	0.7	4
78	The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 323-328.	0.4	18
79	Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 866-873.	0.4	20
80	Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study. <i>Leukemia and Lymphoma</i> , 2014, 55, 533-537.	0.6	16
81	Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1113-1122.	3.3	152
82	HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China. <i>Medical Oncology</i> , 2014, 31, 845.	1.2	16
83	Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma. <i>Cancer Cell International</i> , 2014, 14, 5.	1.8	5
84	Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. <i>British Journal of Haematology</i> , 2014, 165, 300-315.	1.2	24
85	Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 343-355.e6.	0.2	15
86	Impact of prior rituximab on outcomes of autologous stem cell transplantation in patients with relapsed or refractory aggressive B cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. <i>British Journal of Haematology</i> , 2014, 164, 668-674.	1.2	14
87	Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. <i>Leukemia and Lymphoma</i> , 2014, 55, 2228-2240.	0.6	54
89	Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1112-1118.	0.8	201
90	Update on obinutuzumab in the treatment of B-cell malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1507-1517.	1.4	18
91	Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. <i>Journal of Immunology</i> , 2014, 193, 1519-1524.	0.4	46
92	Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. <i>SpringerPlus</i> , 2014, 3, 342.	1.2	3
93	A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014, 25, 2398-2404.	0.6	14
94	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	0.8	1,269

#	ARTICLE	IF	CITATIONS
95	Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1585-1592.	3.3	14
96	Accelerated therapeutic progress in diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2014, 93, 541-556.	0.8	25
97	The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1297-1304.	0.8	53
98	Vincristine-induced vocal cord palsy and successful re-treatment in a patient with diffuse large B cell Lymphoma: a case report. <i>BMC Research Notes</i> , 2014, 7, 318.	0.6	8
99	Diffuse large B-cell lymphoma—treatment approaches in the molecular era. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 12-23.	12.5	333
100	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
101	Suboptimal dosing of rituximab in male and female patients with DLBCL. <i>Blood</i> , 2014, 123, 640-646.	0.6	124
102	Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 279-293.	0.3	7
103	Double Hit Lymphoma – a Case of Unusual Response after Sequential Aggressive Chemotherapy and Review of the Literature. <i>Clinical Medicine Insights: Case Reports</i> , 2014, 7, CCRRep.S11393.	0.3	2
104	HIV-infection impact on clinical—biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. <i>Aids</i> , 2015, 29, 811-818.	1.0	37
105	Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. <i>Haematologica</i> , 2015, 100, 525-533.	1.7	37
107	A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I-II) diffuse large B-cell non-Hodgkin lymphoma: ECOG 3402. <i>British Journal of Haematology</i> , 2015, 170, 679-686.	1.2	19
108	Rituximab with high-dose methotrexate in primary central nervous system lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1149-1154.	2.0	41
109	Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00010.	0.7	6
110	Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S4-20.	1.0	55
111	Prognostic value of CD10, BCL-6, MUM-1, and CD138 in diffuse large B-cell lymphoma. <i>Egyptian Journal of Pathology</i> , 2015, 35, 95-104.	0.0	0
112	ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 610-620.	0.6	9
113	Primary refractory diffuse large B cell lymphoma in the rituximab era. <i>Current Opinion in Oncology</i> , 2015, 27, 377-383.	1.1	16

#	ARTICLE	IF	CITATIONS
114	Management of the lymphomas and myeloma. , 0, , 450-472.		0
115	An Aggressive Transformation to EBV-Positive Hodgkin Lymphoma after Bendamustine-Containing Chemotherapy for Marginal Zone Lymphoma. <i>Journal of Hematology &amp; Thromboembolic Diseases</i> , 2015, 4, .	0.1	0
116	Skeletal Muscle Radio-Density Is an Independent Predictor of Response and Outcomes in Follicular Lymphoma Treated with Chemoimmunotherapy. <i>PLoS ONE</i> , 2015, 10, e0127589.	1.1	41
117	Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0129064.	1.1	14
118	Consolidation Radiotherapy in Stage IE- IIE, Non-Bulky Primary Gastric Diffuse Large B-Cell Lymphoma with Post-Chemotherapy Complete Remission. <i>PLoS ONE</i> , 2015, 10, e0133469.	1.1	8
119	Constitutive NF- $\kappa$ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma. <i>BioMed Research International</i> , 2015, 2015, 1-5.	0.9	27
120	The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis. <i>Acta Haematologica</i> , 2015, 134, 111-118.	0.7	22
121	Ocular Adnexal Diffuse Large B-cell Lymphoma. <i>JAMA Ophthalmology</i> , 2015, 133, 165.	1.4	60
122	Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+non-Hodgkin's lymphoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 21-29.	1.0	4
123	The impact of age on survival of diffuse large B-cell lymphoma – a population-based study. <i>Acta Oncol<sup>3</sup>gica</i> , 2015, 54, 916-923.	0.8	20
124	Management of Diffuse Large B-Cell Lymphoma (DLBCL). <i>Cancer Treatment and Research</i> , 2015, 165, 271-288.	0.2	53
125	CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. <i>Expert Review of Hematology</i> , 2015, 8, 343-354.	1.0	31
126	Utility of interim and end-of-treatment [ <sup>18</sup> F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2579-2584.	0.6	16
127	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. <i>Blood</i> , 2015, 125, 22-32.	0.6	445
128	FDG PET/CT imaging as a biomarker in lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 623-633.	3.3	68
129	Beyond R-CHOP: treatment of double hit, tripple hit, MYC+ $\hat{A}$ NHL?. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 48-51.	0.3	1
130	Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study. <i>International Journal of Cancer</i> , 2015, 137, 658-665.	2.3	36
131	Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma – a Swedish population-based study. <i>Acta Oncol<sup>3</sup>gica</i> , 2015, 54, 924-932.	0.8	19



#	ARTICLE	IF	CITATIONS
132	The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 791-808.	2.5	7
133	Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?. <i>Acta Oncologica</i> , 2015, 54, 953-955.	0.8	3
134	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica</i> , 2015, 100, 955-963.	1.7	75
135	Additional Support for Consolidative Radiotherapy for Diffuse Large B Cell Lymphoma in the Modern Rituximab Era. <i>Acta Haematologica</i> , 2015, 134, 109-110.	0.7	2
136	Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. <i>Annals of Oncology</i> , 2015, 26, 1058-1068.	0.6	67
137	Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. <i>Journal of Clinical Oncology</i> , 2015, 33, 1467-1474.	0.8	56
138	Resultados del tratamiento del linfoma de células del manto con varios regímenes de inmunoterapia: estudio retrospectivo. <i>Revista Colombiana De Cancerología</i> , 2015, 19, 71-80.	0.0	0
139	Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. <i>Annals of Hematology</i> , 2015, 94, 803-812.	0.8	74
140	Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1995-2004.	1.2	22
141	A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. <i>Future Oncology</i> , 2015, 11, 1327-1342.	1.1	61
142	Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study. <i>Annals of Oncology</i> , 2015, 26, 2311-2317.	0.6	22
143	Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. <i>Leukemia Research</i> , 2015, 39, 1187-1191.	0.4	28
144	Consolidative Radiation in DLBCL: Evidence-Based Recommendations. <i>Current Oncology Reports</i> , 2015, 17, 49.	1.8	6
145	The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 511-525.	2.7	1
146	Obinutuzumab in hematologic malignancies: Lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015, 41, 784-792.	3.4	52
147	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	2.9	21
148	Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: Secular trends of a population-based cancer registry from 1998 to 2012. <i>International Journal of Cancer</i> , 2015, 137, 2674-2687.	2.3	23
149	Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v116-v125.	0.6	621

#	ARTICLE	IF	CITATIONS
150	Next-generation prognostic assessment for diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2443-2457.	1.1	8
151	Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Targeted-Preferential Release of Doxorubicin in CXCR4-Expressing Lymphoma Cells. <i>Advanced Functional Materials</i> , 2015, 25, 687-695.	7.8	54
152	Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. <i>Haematologica</i> , 2015, 100, 238-245.	1.7	87
153	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM) is an effective regimen in relapsed diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 219-226.	1.1	11
154	The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 12-25.	0.6	18
155	CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. <i>Journal of Pathology</i> , 2015, 235, 445-455.	2.1	71
156	Antibody Therapy. , 2016, , 550-559.		2
157	Oct2, BCL6, IRF8, OCAB and PU.1 in the Assessment of Prognosis in Diffuse Large B cell Lymphoma Patients. <i>Journal of Molecular Biomarkers &amp; Diagnosis</i> , 2016, 07, .	0.4	1
158	A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient. <i>Stem Cell Investigation</i> , 2016, 3, 25-25.	1.3	3
159	BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5943-5953.	1.0	52
160	An update on newer monoclonal antibodies in lymphoma therapy. <i>Asian Journal of Oncology</i> , 0, 02, 003-007.	0.2	3
161	Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 197-208.	0.7	6
162	Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. <i>Journal of Clinical Oncology</i> , 2016, 34, 2997-3004.	0.8	97
163	Clinical approach to diffuse large B cell lymphoma. <i>Blood Reviews</i> , 2016, 30, 477-491.	2.8	26
164	Lenalidomide in combination with ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. <i>British Journal of Haematology</i> , 2016, 173, 245-252.	1.2	24
165	Adolescent and young adult non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 637-650.	1.2	30
167	Central nervous system relapse in diffuse large B cell lymphoma: Risk factors. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 74-80.	0.1	3
168	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2484-2492.	0.8	106

#	ARTICLE	IF	CITATIONS
169	Obinutuzumab for the treatment of indolent lymphoma. <i>Future Oncology</i> , 2016, 12, 1769-1781.	1.1	8
170	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). <i>BMC Cancer</i> , 2016, 16, 282.	1.1	53
171	FDG-PET imaging in hematological malignancies. <i>Blood Reviews</i> , 2016, 30, 317-331.	2.8	43
172	PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 185-195.	1.2	22
173	B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. <i>Expert Review of Hematology</i> , 2016, 9, 553-561.	1.0	8
175	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. <i>Blood</i> , 2016, 127, 2182-2188.	0.6	145
176	Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 185-194.	0.6	122
177	Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option. <i>Radiation Oncology</i> , 2016, 11, 110.	1.2	28
178	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 4015-4022.	0.8	66
179	EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 529-537.	2.0	74
180	Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 567-576.	2.9	83
181	Anti-CD20 antibody treatment of non-Hodgkin lymphomas. <i>Clinical Immunology</i> , 2016, 172, 101-104.	1.4	21
182	State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1147-1162.	0.9	11
183	Diffuse Large B-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1179-1194.	0.9	6
184	Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model. <i>Annals of Hematology</i> , 2016, 95, 1661-1669.	0.8	23
185	Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 45.	1.3	3
186	Treatment of Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2016, 56, 79-88.	0.3	52
187	Diffuse Large B-Cell Lymphoma Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 196-231.	2.3	76

#	ARTICLE	IF	CITATIONS
188	Paediatric non-Hodgkin lymphoma – perspectives in translational biology. <i>British Journal of Haematology</i> , 2016, 173, 617-624.	1.2	9
189	Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 173, 950-957.	1.2	8
190	Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. <i>Cancer Immunology Research</i> , 2016, 4, 509-519.	1.6	27
191	TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 40.	2.4	19
192	The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2763-2770.	0.6	10
193	Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1397-1402.	2.0	6
194	Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. <i>Acta Haematologica</i> , 2016, 136, 76-84.	0.7	6
195	Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90Yttrium-britumomab-tiuxetan. <i>European Journal of Haematology</i> , 2016, 97, 576-582.	1.1	8
196	CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma – a meta-analysis of randomized controlled trials. <i>Acta Oncologica</i> , 2016, 55, 77-84.	0.8	4
197	Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment. <i>Leukemia and Lymphoma</i> , 2016, 57, 2033-2036.	0.6	10
198	Diffuse large B-cell lymphoma with MYC gene rearrangements. <i>European Journal of Cancer</i> , 2016, 55, 140-146.	1.3	27
199	Targeting B-cell non Hodgkin lymphoma: New and old tricks. <i>Leukemia Research</i> , 2016, 42, 93-104.	0.4	51
200	Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1697-1708.	0.6	5
201	Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone – compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2016, 58, 112-121.	1.3	64
202	Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 390-397.	0.6	54
203	Rare case of primary pleural lymphoma presenting with pleural effusion. <i>Thoracic Cancer</i> , 2016, 7, 145-150.	0.8	10
204	Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 175-181.	0.2	27
205	Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy. <i>Expert Review of Hematology</i> , 2016, 9, 471-477.	1.0	18

#	ARTICLE	IF	CITATIONS
206	The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2016, 57, 1876-1882.	0.6	11
207	Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 4.	1.3	18
208	Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1209-1219.	3.3	217
209	Prognostic value of negative interim 2-[18F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma. <i>Clinical Radiology</i> , 2016, 71, 280-286.	0.5	12
210	Non-Hodgkin's Lymphoma. , 2016, , 1524-1546.e7.		2
211	Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes. <i>Journal of Clinical Oncology</i> , 2016, 34, 69-75.	0.8	79
212	Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 276-282.	0.6	14
213	Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 842-851.	0.6	7
214	Barriers to the Collaboration Between Hematologists and Palliative Care Teams on Relapse or Refractory Leukemia and Malignant Lymphoma Patients' Care. <i>American Journal of Hospice and Palliative Medicine</i> , 2016, 33, 977-984.	0.8	20
215	MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients. <i>Tumor Biology</i> , 2016, 37, 1237-1244.	0.8	6
217	Validation of the NCCN-IPI in both <i>de novo</i> and transformed diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 214-217.	0.6	4
218	Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22,466 survivors in Israel with 30 years of follow-up. <i>Hematological Oncology</i> , 2017, 35, 599-607.	0.8	13
219	Beta2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 440-446.	0.8	27
220	Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B cell lymphoma: a Swedish Lymphoma Registry study. <i>Hematological Oncology</i> , 2017, 35, 151-157.	0.8	12
221	Treatment approaches of hard-to-treat non-Hodgkin lymphomas. <i>Expert Review of Hematology</i> , 2017, 10, 259-273.	1.0	9
222	Primary mediastinal large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 318-327.	2.0	77
223	Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients. <i>Medical Oncology</i> , 2017, 34, 29.	1.2	9
224	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e137-e146.	2.2	28

#	ARTICLE	IF	CITATIONS
226	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9
227	<i>Catharanthus roseus</i> : The Cancer-Fighting Medicine. , 2017, , 121-151.		1
228	Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2833-2844.	0.6	13
230	Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 298-304.	2.9	60
231	Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion. <i>Clinical Therapeutics</i> , 2017, 39, 1221-1232.e4.	1.1	17
232	Rituximab: 13 open questions after 20years of clinical use. <i>Cancer Treatment Reviews</i> , 2017, 53, 38-46.	3.4	48
233	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. <i>Advances in Therapy</i> , 2017, 34, 2232-2273.	1.3	407
234	Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of <sc>CHOP</sc> compared to first-line autologous transplantation. <i>British Journal of Haematology</i> , 2017, 178, 927-935.	1.2	8
235	Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 179, 75-82.	1.2	15
236	Peripheral blood lymphocyte/monocyte ratio following completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2017, 96, 237-243.	0.8	3
237	Non-Hodgkin Lymphoma. <i>Pediatric Oncology</i> , 2017, , 69-117.	0.5	2
238	Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline. <i>Clinical Oncology</i> , 2017, 29, e13-e28.	0.6	14
239	Radiation Therapy in Hematologic Malignancies. , 2017, , .		0
240	Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma. <i>JAMA Oncology</i> , 2017, 3, 83.	3.4	64
241	Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. <i>Blood Advances</i> , 2017, 1, 1945-1958.	2.5	25
242	Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 259-264.	0.9	1
243	MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	10
244	TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP. <i>BMC Cancer</i> , 2017, 17, 743.	1.1	9

#	ARTICLE	IF	CITATIONS
245	Transformation of primary cutaneous follicle centre lymphoma into primary cutaneous diffuse large B-cell lymphoma of other type. <i>Postepy Dermatologii I Alergologii</i> , 2017, 34, 625-628.	0.4	2
246	Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1142-1154.	3.3	106
247	Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2018, 97, 999-1007.	0.8	50
248	Efficacy and safety of administering pediatric treatment to adolescent patients with mature B-cell non-Hodgkin lymphoma within the Japanese Pediatric Leukemia/Lymphoma Study Group clinical trial. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27068.	0.8	1
249	Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 432-439.	0.9	1
251	Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1126-1132.	0.4	10
252	Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. <i>Haematologica</i> , 2018, 103, 857-864.	1.7	27
253	Limited-stage DLBCL: it's patient selection. <i>Blood</i> , 2018, 131, 155-156.	0.6	3
254	Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 85-96.	3.3	13
255	Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. <i>Cancer Medicine</i> , 2018, 7, 270-281.	1.3	44
256	Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 125-135.e3.	0.2	6
257	Lymphoma of Bone. <i>JBJS Reviews</i> , 2018, 6, e1-e1.	0.8	2
258	Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes. <i>Hematological Oncology</i> , 2018, 36, 533-542.	0.8	5
259	Retrospective Analysis of a New Prognostic Score for Diffuse Large B-Cell Lymphoma Based on Interim Positron Emission Tomography-Computed Tomography. <i>Acta Haematologica</i> , 2018, 139, 148-157.	0.7	3
260	Analysis of the prognostic value of BMI and the difference in its impact according to age and sex in DLBCL patients. <i>Hematological Oncology</i> , 2018, 36, 76-83.	0.8	9
261	Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 93-97.	0.8	22
262	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , 2018, 32, 353-363.	3.3	36
263	A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Hematological Oncology</i> , 2018, 36, 49-55.	0.8	12

#	ARTICLE	IF	CITATIONS
264	Relapse in stage I(E) diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 416-421.	0.8	9
265	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 174-181.	0.6	121
266	Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. <i>Leukemia and Lymphoma</i> , 2018, 59, 1375-1383.	0.6	27
267	Phase I dose escalation study of the anti-CD2 monoclonal antibody, sipilizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 1466-1469.	0.6	10
268	Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2018, 59, 1153-1162.	0.6	6
269	Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions. <i>Journal of Immunotherapy</i> , 2018, 41, 19-31.	1.2	23
270	Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities. <i>Annals of Hematology</i> , 2018, 97, 267-276.	0.8	11
271	Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China. <i>Chinese Medical Journal</i> , 2018, 131, 1767-1775.	0.9	9
272	TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis. <i>Oncotarget</i> , 2018, 9, 19555-19568.	0.8	10
273	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018, 36, 2593-2602.	0.8	59
274	Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 32383-32399.	0.8	9
275	RIVA a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 619.	0.7	7
276	Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. <i>Cancer Science</i> , 2018, 109, 3943-3952.	1.7	26
277	Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging. <i>Analytical Chemistry</i> , 2018, 90, 14198-14206.	3.2	26
278	Lymphoma in Adolescents and Young Adults. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 285-300.	1.0	7
279	Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma. <i>CNS Oncology</i> , 2018, 7, CNS19.	1.2	4
280	Radiation Therapy in Diffuse Large B-Cell Lymphoma. , 2018, , 1-14.		0
281	Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 52.	1.3	13



#	ARTICLE	IF	CITATIONS
282	Primary diffuse large B-cell lymphoma in the maxilla. <i>Medicine (United States)</i> , 2018, 97, e10707.	0.4	14
283	Non-Hodgkin's Lymphoma. , 2018, , 757-768.		0
284	Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 216-223.	0.6	6
285	Successful role of radiation therapy: Account for every single gray and make every single gray count. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 217-232.	0.7	1
286	Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 163.	1.3	238
287	Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. <i>Oncology Letters</i> , 2018, 16, 1602-1614.	0.8	22
288	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2018, 93, 953-962.	2.0	75
289	<sup>18</sup>F-FDG PET/CT in the management of lymphomas: current status and future directions. <i>Journal of Internal Medicine</i> , 2018, 284, 358-376.	2.7	79
290	NHL in adolescents and young adults: A unique population. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27073.	0.8	19
291	Anti-CD20 monoclonal antibodies: reviewing a revolution. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2820-2841.	1.4	68
292	Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?. <i>Annals of Hematology</i> , 2018, 97, 2129-2135.	0.8	13
293	Rituximab in primary central nervous system lymphoma—A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	0.8	54
294	<p></p>Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date<p></p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4543-4554.	1.0	6
295	Rituximab-PECC induction followed by <sup>90</sup> Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. <i>British Journal of Haematology</i> , 2019, 187, 347-355.	1.2	8
296	Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 207-218.	1.2	17
297	Rituximab biosimilar RTX83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. <i>Leukemia and Lymphoma</i> , 2019, 60, 3375-3385.	0.6	22
298	Cost burden of diffuse large B-cell lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 645-661.	0.7	14
299	Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature. <i>Expert Review of Hematology</i> , 2019, 12, 1095-1105.	1.0	5

#	ARTICLE	IF	CITATIONS
300	The opportunistic effect of exosomes on Non-Hodgkin Lymphoma microenvironment modulation. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102825.	2.0	9
302	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
304	Disrupting myddosome assembly in diffuse large B-cell lymphoma cells using the MYD88 dimerization inhibitor ST2825. <i>Oncology Reports</i> , 2019, 42, 1755-1766.	1.2	9
305	Immunotherapy in People With HIV and Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2060.	2.2	37
306	The role of autologous stem cell transplantation in diffuse large B-cell lymphoma. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e33.	0.6	2
307	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 1819-1827.	0.8	44
308	Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome. <i>Acta Oncologica</i> , 2019, 58, 1170-1177.	0.8	11
309	Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). <i>Leukemia and Lymphoma</i> , 2019, 60, 2669-2678.	0.6	20
310	Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1743-1753.	0.8	3
311	Landmark Trials in Oncology. , 2019, , .		0
312	Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 407-418.	1.0	4
313	Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras. <i>European Journal of Haematology</i> , 2019, 102, 457-464.	1.1	5
314	Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. <i>Frontiers in Oncology</i> , 2019, 9, 107.	1.3	34
315	Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 677-687.	1.0	13
316	Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP. <i>Hematological Oncology</i> , 2019, 37, 333-344.	0.8	38
317	Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1417-1427.	3.3	49
318	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	0.8	266
319	The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. <i>Cancer Medicine</i> , 2019, 8, 1103-1109.	1.3	15

#	ARTICLE	IF	CITATIONS
320	Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-9.	1.0	15
321	Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas. <i>Viruses</i> , 2019, 11, 1161.	1.5	6
322	Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 170-174.	0.3	2
323	Chemoimmunotherapy for localised low-risk diffuse large B-cell lymphoma. <i>Lancet, The</i> , 2019, 394, 2208-2209.	6.3	0
324	CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. <i>HemaSphere</i> , 2019, 3, e185.	1.2	33
325	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?. <i>HemaSphere</i> , 2019, 3, e284.	1.2	9
326	Cancer and AIDS. , 2019, , .		0
327	Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. <i>Leukemia and Lymphoma</i> , 2019, 60, 2062-2066.	0.6	6
328	Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 1-16.	2.0	9
329	Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENISE-Mega-CHOEP trial. <i>British Journal of Haematology</i> , 2019, 184, 760-768.	1.2	9
330	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	0.6	3
331	Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 304-316.	0.6	11
332	Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 335-344.	0.8	8
333	A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. <i>Leukemia</i> , 2020, 34, 543-552.	3.3	26
334	Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100502.	1.0	12
335	The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2020, 25, e321-e327.	1.9	81
336	CAR-T Cell Therapy for Lymphoma: How Does Radiation Therapy Fit In?. <i>Practical Radiation Oncology</i> , 2020, 10, e155-e158.	1.1	8
337	Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 71-77.	0.3	7

#	ARTICLE	IF	CITATIONS
338	Non-Hodgkin Lymphomas. , 2020, , 1926-1947.e5.		0
339	Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia and Lymphoma</i> , 2020, 61, 1119-1125.	0.6	5
340	A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway. <i>BMC Cancer</i> , 2020, 20, 1.	1.1	264
341	Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa. <i>Cancer Medicine</i> , 2020, 9, 77-83.	1.3	15
342	Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 272-277.	2.0	2
343	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NCRI phase II randomised LEGEND trial. <i>Annals of Hematology</i> , 2020, 99, 105-112.	0.8	6
344	New murine models of aggressive lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 788-798.	0.6	4
345	A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. <i>Lancet Haematology</i> , 2020, 7, e838-e850.	2.2	12
346	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2299-2305.	2.0	4
347	CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies. <i>Lancet Haematology</i> , 2020, 7, e690-e696.	2.2	24
348	Two cases of spindle cell variant diffuse large B-cell lymphoma of the uterine cervix. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100611.	0.3	4
349	Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis. <i>International Journal of Medical Sciences</i> , 2020, 17, 2735-2743.	1.1	11
350	Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI $\geq 5$ ) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. <i>Annals of Oncology</i> , 2020, 31, 1251-1259.	0.6	41
351	Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. <i>Leukemia</i> , 2020, 34, 2576-2591.	3.3	18
352	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	0.8	75
353	Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients. <i>Cancer Management and Research</i> , 2020, Volume 12, 11515-11522.	0.9	8
354	A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. <i>Frontiers of Medicine</i> , 2020, 14, 711-725.	1.5	8
355	Primary diffuse large B cell lymphoma of Uterine Cervix: Treatment outcomes of a rare entity with literature review. <i>Cancer Reports</i> , 2020, 3, e1264.	0.6	12

#	ARTICLE	IF	CITATIONS
356	Potential "significance"™ of monoclonal gammopathy of "undetermined significance"™ during COVID-19 pandemic. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 85, 102481.	0.6	8
357	Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. <i>Clinical Epigenetics</i> , 2020, 12, 160.	1.8	23
358	Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09). <i>Annals of Hematology</i> , 2020, 99, 2831-2836.	0.8	3
359	Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients. <i>BMC Cancer</i> , 2020, 20, 1041.	1.1	5
360	Treatment of Early (Limited)-Stage DLBCL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S34-S36.	0.2	1
361	The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2020, 9, 7072-7082.	1.3	4
362	Diffuse Large B-Cell Lymphoma. , 0, , .		0
363	Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1684-1690.	0.5	2
364	Network meta-analysis of targeted therapies for diffuse large B cell lymphoma. <i>BMC Cancer</i> , 2020, 20, 1218.	1.1	3
365	Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2020, 20, 439.	1.1	19
366	The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. <i>Blood Advances</i> , 2020, 4, 2011-2017.	2.5	12
367	Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX/IVAC: Results of a phase 2 UK NCRI trial. <i>EJHaem</i> , 2020, 1, 133-141.	0.4	5
368	Immunotherapy in Hematologic Malignancies. <i>Current Oncology</i> , 2020, 27, 124-131.	0.9	20
369	On point in primary CNS lymphoma. <i>Hematological Oncology</i> , 2020, 38, 640-647.	0.8	10
370	Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis. <i>Haematologica</i> , 2021, 106, 1923-1931.	1.7	7
371	Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 740-748.	2.0	10
372	Evidence-based follow-up in patients with Hodgkin's lymphoma and aggressive B-cell non-Hodgkin's lymphoma. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 55-59.	0.3	1
373	Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group. <i>Leukemia and Lymphoma</i> , 2020, 61, 2614-2621.	0.6	1

#	ARTICLE	IF	CITATIONS
374	Radiotherapy for Non-Hodgkin Lymphomas. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 217-230.	1.0	11
375	Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. <i>Frontiers in Oncology</i> , 2020, 10, 989.	1.3	15
376	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 435-445.	2.0	35
377	The Thorax. <i>Cancer Dissemination Pathways</i> , 2020, , .	0.0	0
378	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	1.3	17
379	Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 309-317.	0.8	26
380	EHA evaluation of the ESMO Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	2.0	10
381	EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2020, 25, 894-902.	1.9	37
382	Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2020, 99, 1311-1319.	0.8	4
383	A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 38.	6.9	18
384	Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. <i>Cancer Medicine</i> , 2020, 9, 3765-3774.	1.3	44
385	FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. <i>British Journal of Haematology</i> , 2021, 192, 504-513.	1.2	27
386	Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 55.e1-55.e7.	0.6	7
387	Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 323-329.	0.6	2
388	Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma – data from phase II and III trials of the DSHNHL (German High-Grade) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.8	5
389	Obinutuzumab-related adverse events: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2021, 39, 215-221.	0.8	17
390	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	0.6	48
391	R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience. <i>Annals of Hematology</i> , 2021, 100, 1517-1524.	0.8	5

#	ARTICLE	IF	CITATIONS
392	A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. <i>Leukemia and Lymphoma</i> , 2021, 62, 549-559.	0.6	5
393	Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures. <i>Osteoporosis International</i> , 2021, 32, 281-291.	1.3	10
394	Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. <i>British Journal of Haematology</i> , 2021, 193, 52-62.	1.2	14
395	Why R-CHOP is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1302-1312.	0.6	5
396	Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial. <i>Cancer Biology and Medicine</i> , 2021, 19, 1089-1099.	1.4	1
397	Management of Non-Hodgkin's Lymphoma. , 2021, , 27-37.		0
398	Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. <i>Blood Cancer Journal</i> , 2021, 11, 9.	2.8	32
399	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence. <i>ESMO Open</i> , 2021, 6, 100012.	2.0	5
400	CNS relapse in DLBCL: a calculable risk?. <i>Blood</i> , 2021, 137, 1011-1012.	0.6	2
401	A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. <i>Blood Advances</i> , 2021, 5, 984-993.	2.5	9
402	Stage II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1840-1849.	0.6	1
403	Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma. <i>Cardio-Oncology</i> , 2021, 7, 6.	0.8	2
404	Limited-stage diffuse large B-cell lymphoma: current management and challenges. <i>British Journal of Haematology</i> , 2021, 194, 508-517.	1.2	2
405	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , 2021, 11, 648655.	1.3	19
406	Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 162-169.	0.2	3
407	The Value of Nutritional Status in the Prognostic Analysis of Patients with AIDS-Related Lymphoma. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1105-1113.	1.1	7
408	Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial. <i>Advances in Therapy</i> , 2021, 38, 1889-1903.	1.3	9
409	Real-World Data (RWD) on the 3-Year Follow-Up Outcomes of Different CNS Prophylaxis Strategies Across CNS-IPI Risk Groups in Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma. <i>JCO Global Oncology</i> , 2021, 7, 486-494.	0.8	4

#	ARTICLE	IF	CITATIONS
410	Ferroptosis-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Diffuse Large B-Cell Lymphoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 609-619.	0.4	8
411	Myocardial infarction in diffuse large B-cell lymphoma patients – a population-based matched cohort study. <i>Journal of Internal Medicine</i> , 2021, 290, 1048-1060.	2.7	10
412	A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. <i>British Journal of Cancer</i> , 2021, 125, 402-412.	2.9	7
413	Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 711-719.	0.2	2
414	Treatment resistance in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2151-2165.	3.3	44
415	Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study. <i>British Journal of Haematology</i> , 2021, 193, 906-914.	1.2	12
416	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. <i>Cancer Medicine</i> , 2021, 10, 5101-5109.	1.3	4
417	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. <i>International Journal of Hematologic Oncology</i> , 2021, 10, IJH33.	0.7	11
418	Cure with heart in mind!. <i>Journal of Internal Medicine</i> , 2021, 290, 947-948.	2.7	0
419	High-dose Chemotherapy Combined with Autologous Hematopoietic Stem Cell Transplantation as Frontline Therapy for Intermediate/High-risk Diffuse Large B Cell Lymphoma. <i>Current Medical Science</i> , 2021, 41, 465-473.	0.7	1
421	Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial. <i>The Lancet Global Health</i> , 2021, 9, e1008-e1016.	2.9	15
422	Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 138, 1110-1119.	0.6	30
423	Safety and efficacy of rituximab in Malawi: a case for multicentre oncology clinical trials in Africa?. <i>The Lancet Global Health</i> , 2021, 9, e895-e896.	2.9	2
424	Epstein-Barr Virus Positive B-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract. <i>Cancers</i> , 2021, 13, 3815.	1.7	14
425	Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 106.	6.9	22
426	The optimal use of PET/CT in the management of lymphoma patients. <i>British Journal of Radiology</i> , 2021, 94, 20210470.	1.0	8
427	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	0.8	37
428	SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status. <i>Annals of Oncology</i> , 2021, 32, 1400-1409.	0.6	18



#	ARTICLE	IF	CITATIONS
429	<sc>MYC</sc> and p53 expression highlight starry pattern as a favourable prognostic feature in <sc>R-CHOP</sc>-treated diffuse large B-cell lymphoma. Journal of Pathology: Clinical Research, 2021, 7, 604-615.	1.3	5
430	Improved Progression-Free Survival for Bulky and Non-Bulky Advanced Stage Diffuse Large B-Cell Lymphoma With Consolidative Radiation Therapy: A Bi-Institutional Analysis. Cureus, 2021, 13, e17107.	0.2	1
431	Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China. Infectious Agents and Cancer, 2021, 16, 57.	1.2	5
432	Polymeric nanomedicines targeting hematological malignancies. Journal of Controlled Release, 2021, 337, 571-588.	4.8	15
433	Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 2022, 52, 1609-1623.	0.5	6
434	The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Annals of Hematology, 2021, 100, 2733-2744.	0.8	7
435	R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2. Journal of Cancer, 2021, 12, 2059-2064.	1.2	1
436	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 2020, 126, 2279-2287.	2.0	17
437	Diffuse Large B-Cell Lymphomas in Older Adults. , 2020, , 583-612.		1
438	Non-Hodgkin Lymphoma. , 2014, , 2033-2059.e8.		1
439	An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. Blood Cancer Discovery, 2021, 2, 70-91.	2.6	21
440	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. Journal of Clinical Investigation, 2016, 126, 3351-3362.	3.9	133
441	Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre. Journal of International Medical Research, 2018, 46, 883-894.	0.4	7
442	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology American Society of Hematology Education Program, 2012, 2012, 402-9.	0.9	44
443	Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?. Hematology American Society of Hematology Education Program, 2012, 2012, 410-6.	0.9	20
444	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology American Society of Hematology Education Program, 2012, 2012, 402-409.	0.9	48
445	CD5-positive diffuse large B-cell lymphoma showing prominent intra-sinusoidal infiltration in the bone marrow, successfully treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone in combination with rituximab. Tenri Medical Bulletin, 2013, 16, 31-39.	0.1	2
446	A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent. PLoS ONE, 2014, 9, e102594.	1.1	24

#	ARTICLE	IF	CITATIONS
447	Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkinâ€™s Lymphoma: Correlation with Long-Term Survival. PLoS ONE, 2014, 9, e106745.	1.1	18
448	A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma. PLoS ONE, 2017, 12, e0183969.	1.1	12
449	Passage of Humanized Monoclonal Antibodies Across the Blood- Brain Barrier: Relevance in the Treatment of Cancer Brain Metastases?. Journal of Applied Biopharmaceutics and Pharmacokinetics, 2015, 2, 50-58.	0.1	3
451	A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. Oncotarget, 2017, 8, 47007-47019.	0.8	26
452	Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation. In Vivo, 2018, 32, 413-417.	0.6	4
453	A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes. Radiology and Oncology, 2019, 53, 473-479.	0.6	3
454	Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2343-2348.	0.5	2
455	Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkinâ€™s lymphoma. World Journal of Gastroenterology, 2014, 20, 5165.	1.4	11
456	Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Reports, 2020, 12, 8296.	0.3	2
457	Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era. Journal of Cancer Research and Therapeutics, 2018, 14, S248-S253.	0.3	11
458	Primary breast lymphoma: A single-institute experience in Taiwan. Biomedical Journal, 2014, 37, 321.	1.4	10
459	Diffuse large B-cell lymphoma: Saudi Lymphoma Group's clinical practice guidelines for diagnosis, management and follow-up. Saudi Journal of Medicine and Medical Sciences, 2019, 7, 209.	0.3	2
460	Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study. Cancer Research and Treatment, 2018, 50, 1051-1063.	1.3	20
461	Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Cancer Research and Treatment, 2019, 51, 919-932.	1.3	14
462	Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland. Swiss Medical Weekly, 2013, 143, w13748.	0.8	10
463	Primary Diffuse Large B-cell Lymphoma of the Sigmoid Colon. Cureus, 2019, 11, e5048.	0.2	9
464	Advanced-stage Hodgkin lymphoma: have effective therapy and modern imaging changed the significance of bulky disease?. Leukemia and Lymphoma, 2021, 62, 1554-1562.	0.6	2
465	SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75Åyears or older with newly diagnosed aggressive non-Hodgkin lymphomas â€“ Aiming to improve therapy, outcomes, and validate a prospective frailty tool. Journal of Geriatric Oncology, 2022, 13, 258-264.	0.5	9

#	ARTICLE	IF	CITATIONS
466	Diffuse Large B-Cell Lymphoma. , 2013, , 177-202.		0
467	A clinical study of diagnostic biopsies of the cervical lymph node. Journal of Japan Society for Head and Neck Surgery, 2014, 24, 101-107.	0.0	2
468	Lymphomes : principes thÃ©rapeutiques et imagerie post-thÃ©rapeutique. , 2014, , 265-298.		0
469	Successful Salvage Treatment for Isolated Brain Parenchymal Relapse due to Diffuse Large B Cell Lymphoma. Korean Journal of Medicine, 2015, 88, 218.	0.1	1
472	Diffuse Large B-Cell Lymphoma. , 2017, , 29-43.		0
474	Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes. Journal of Hematology (Brossard, Quebec), 2017, 6, 33-43.	0.4	5
475	Infiltrative Rash Secondary to Leukemic-Phase Diffuse Large B-Cell Lymphoma With t(14;18), CDKN2A and MLL Deletion. Journal of Hematology (Brossard, Quebec), 2017, 6, 90-95.	0.4	0
476	Diffuse Large B-Cell Lymphomas in Older Adults. , 2018, , 1-31.		0
477	Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era. Journal of Cancer Research and Therapeutics, 2018, 14, 1397-1402.	0.3	0
478	Zastosowanie infuzyjnego schematu chemioterapii DA-EPOCH w leczeniu chÃ³roniakÃ³w agresywnych. Acta Haematologica Polonica, 2018, 49, 85-91.	0.1	0
479	Therapy of Cancer and Retroviral Diseases. , 2019, , 65-158.		1
480	Aggressive Lymphoma. , 2019, , 387-399.		0
481	CD20-Negative Aggressive Lymphomas. Mechanical Engineering Series, 2019, , 213-226.	0.1	0
482	Landmark Trials in Selected Lymphomas. , 2019, , 241-272.		0
483	Primary mediastinal large B-Cell lymphoma: Saudi Lymphoma Group's clinical practice guidelines for diagnosis, management and follow-up. Saudi Journal of Medicine and Medical Sciences, 2019, 7, 231.	0.3	1
484	The Lower Peripheral Blood Lymphocyte to Monocyte Ratio Following Completion of First Line Chemotherapy Is a Risk Factor for Predicting Relapse in Patients with Diffuse Large B-Cell Lymphoma. Journal of Cancer Therapy, 2019, 10, 53-68.	0.1	0
485	Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. Korean Journal of Internal Medicine, 2019, 34, 894-901.	0.7	0
486	Renal involvement in diffuse large B-cell lymphoma: A case report. Marmara Medical Journal, 0, ,	0.2	0

#	ARTICLE	IF	CITATIONS
487	Other Mediastinal Tumors. Cancer Dissemination Pathways, 2020, , 127-157.	0.0	0
488	Saudi lymphoma group's clinical practice guidelines for diagnosis, management and follow-up of patients with various types of lymphoma during the Coronavirus Disease 2019 pandemic. Saudi Journal of Medicine and Medical Sciences, 2020, 8, 227.	0.3	1
489	Prognostic value of interim (18)F-FDG PET/CT in diffuse large B-cell lymphoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 95-101.	0.7	6
490	New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treatment Strategies Hematology, 2012, 2, 68-73.	0.0	2
491	Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 459-65.	0.7	9
492	Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 516-23.	0.7	2
493	Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 17515-22.	1.3	10
494	Therapeutic Options in Diffuse Large B-Cell Lymphoma - A Retrospective Study and Review of the Literature. Current Health Sciences Journal, 2017, 43, 269-274.	0.2	0
500	Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma. Cancer Management and Research, 2021, Volume 13, 8831-8839.	0.9	2
501	Outcomes of Diffuse Large B-Cell Non-Hodgkin's Lymphoma After Gemcitabine-Based Second Salvage Chemotherapy: A Single-Center Study. Cureus, 2021, 13, e19699.	0.2	0
502	COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review. World Journal of Virology, 2021, 10, 312-325.	1.3	25
503	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions. Cancers, 2021, 13, 5827.	1.7	18
504	Associa�o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma. Hematology, Transfusion and Cell Therapy, 2021, 43, S22-S29.	0.1	0
505	Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	0
506	HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 Expression. , 2021, , .		3
507	Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis. Annals of Hematology, 2022, 101, 595-605.	0.8	2
508	Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the RITL (Regional Tuscan Lymphoma network). European Journal of Haematology, 2022, 108, 383-390.	1.1	4
509	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. Blood Advances, 2022, 6, 2745-2756.	2.5	3

#	ARTICLE	IF	CITATIONS
510	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	13.9	278
511	Rare incidence of diffuse large B-cell lymphoma (DLBCL) with bilateral breast and testicular involvement in a male patient: A case report and review of the literature. <i>Current Problems in Cancer Case Reports</i> , 2022, 5, 100142.	0.1	0
512	Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma. <i>European Journal of Haematology</i> , 2022, 108, 403-412.	1.1	0
513	Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article. <i>International Immunopharmacology</i> , 2022, 105, 108580.	1.7	5
515	Limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 822-834.	0.6	22
516	DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 698-709.	0.3	1
517	Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma. <i>Phenomics</i> , 2022, 2, 102-118.	0.9	8
518	Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma. <i>Antibodies</i> , 2022, 11, 15.	1.2	3
519	Evolution of therapy for limited stage diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 33.	2.8	9
520	Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. <i>Seminars in Cancer Biology</i> , 2022, 86, 607-623.	4.3	10
521	Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. <i>Cancers</i> , 2022, 14, 1469.	1.7	6
522	Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018. <i>Blood Cancer Journal</i> , 2022, 12, 38.	2.8	6
523	Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
524	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
525	High grade non-germinal centre-like diffuse large B-cell lymphoma double expressor presenting as a hydrocoele. <i>BMJ Case Reports</i> , 2021, 14, e247381.	0.2	1
526	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2021, , .	1.3	4
527	Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab. <i>Cancers</i> , 2022, 14, 1917.	1.7	9
528	Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial. <i>BMC Cancer</i> , 2022, 22, 403.	1.1	1

#	ARTICLE	IF	CITATIONS
529	Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e730-e737.	0.2	6
530	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabl9171.	4.7	30
531	New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1848-1858.	0.5	5
541	Nomogram-Based Prediction of Overall and Cancer-Specific Survival in Patients with Primary Bone Diffuse Large B-Cell Lymphoma: A Population-Based Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-9.	0.5	3
542	Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 583-595.	1.1	4
543	Short- and long-term outcomes from the upfront high-dose chemotherapy, followed by autologous hematopoietic stem cell transplantation in diffuse large B-cell lymphoma. <i>Meditinskiy Sovet</i> , 2022, , 104-116.	0.1	0
544	Immunophenotypic Landscape and Prognosis-Related mRNA Signature in Diffuse Large B Cell Lymphoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
545	Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 610-617.	0.6	6
546	Long non-coding RNA TRIM52-AS1 sponges microRNA-577 to facilitate diffuse large B cell lymphoma progression via increasing TRIM52 expression. <i>Human Cell</i> , 2022, 35, 1234-1247.	1.2	3
547	Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211033.	1.1	11
549	Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions. <i>Current Opinion in Hematology</i> , 2022, 29, 225-232.	1.2	3
550	Balancing the Therapeutic Ratio in DLBCL Requires Appropriate, Individualized Patient Selection Rather Than Broad Elimination of Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 479-488.	0.4	5
551	Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 7502-7508.	0.3	1
552	Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211104.	0.5	2
553	Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission. <i>British Journal of Cancer</i> , 0, , .	2.9	1
555	Primary pleural lymphoma — A rare diagnosis. <i>Pulmonology</i> , 2022, 29, 94-94.	1.0	0
556	Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
557	Factors Associated with Chemotherapy-induced Neutropenia in Diffuse Large B-cell Lymphoma Patients Undergoing Combination Chemotherapy: A Case-Control Study. <i>Asian Oncology Nursing</i> , 2022, 22, 153.	0.2	0

#	ARTICLE	IF	CITATIONS
558	Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018). , 2023, 1, 3-11.		4
559	Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. JCO Global Oncology, 2022, , .	0.8	2
560	mTOR inhibition amplifies the anti-lymphoma effect of PI3K $\hat{2}$ / $\hat{1}$ blockage in diffuse large B-cell lymphoma. Leukemia, 2023, 37, 178-189.	3.3	7
561	A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances, 2023, 7, 1137-1145.	2.5	5
562	Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma. Leukemia, 0, , .	3.3	1
563	Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis. Pharmacological Research, 2023, 187, 106592.	3.1	1
564	Predictors of response to axicabtagene $\hat{c}$ iloleucel CAR T cells in aggressive B cell lymphomas: A real $\hat{c}$ world study. Journal of Cellular and Molecular Medicine, 2022, 26, 5976-5983.	1.6	3
565	Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options. OncoTargets and Therapy, 0, Volume 15, 1481-1501.	1.0	11
566	Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma. JCI Insight, 2023, 8, .	2.3	13
567	<b>Polatuzumab vedotin with infusional chemotherapy (Pola-DA-EPCH-R) for untreated aggressive B-cell non-Hodgkin lymphomas</b>. Blood Advances, 0, , .	2.5	1
568	Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma. Bone Marrow Transplantation, 2023, 58, 440-442.	1.3	1
569	Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2023, 41, 903-913.	0.8	7
570	Serum miR $\hat{c}$ 146a level is a potential biomarker in predicting the outcome of diffuse large B $\hat{c}$ cell lymphoma. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	1
572	The new German evidence-based guideline on diffuse large B-cell lymphoma $\hat{c}$ key aspects for radiation oncologists. Strahlentherapie Und Onkologie, 2023, 199, 115-120.	1.0	4
573	Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis. Frontiers in Immunology, 0, 13, .	2.2	1
574	Primary central nervous system CD20-negative diffuse large B-cell lymphoma: a case report. BMC Neurology, 2022, 22, .	0.8	0
575	Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma. Cancer Investigation, 0, , 1-10.	0.6	0
576	Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/ DSHNHL analysis. Blood Advances, 0, , .	2.5	3

#	ARTICLE	IF	CITATIONS
577	Prognostic value of metabolic tumor volume and lesion dissemination from baseline PET/CT in patients with diffuse large B-cell lymphoma: Further risk stratification of the group with low-risk and high-risk NCCN-IPI. <i>European Journal of Radiology</i> , 2023, 163, 110798.	1.2	0
578	A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma. <i>Pathology and Oncology Research</i> , 0, 29, .	0.9	1
579	Patients and Familiesâ€™ Participation in Multidisciplinary Tumor Conferences Improves Patient and Family-Focused Cancer Care: Lessons Learned From a Debate on the Role of Radiation Therapy in Primary Mediastinal Non-Hodgkin Lymphoma. <i>Cureus</i> , 2023, , .	0.2	1
580	Association Between the Neutrophil-to-Lymphocyte Ratio and Infection and Survival in Diffuse Large B Cell Lymphoma. <i>In Vivo</i> , 2023, 37, 948-954.	0.6	2
581	Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study. <i>Cancer Research and Treatment</i> , 0, , .	1.3	0
582	Clinicopathological characteristics, local treatment, and prognostic factors in IE/IIIE primary breast lymphoma: a retrospective study of 67 patients. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	1
583	Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study. <i>Oncologist</i> , 2023, 28, e756-e764.	1.9	0
617	Diffuse Large B-Cell Lymphoma. , 2023, , .		0